Inês Martins holds a BSc in Cell and Molecular Biology from Universidade Nova de Lisboa and is currently finishing her PhD in Biomedical Sciences at Universidade de Lisboa. Her work has been focused on blood vessels and their role in both hematopoiesis and cancer development.
Based on preliminary positive safety data, a Safety Review Committee has recommended that a Phase 1/1b clinical trial be continued with TG1050, an immunotherapy candidate being developed by Transgene for ... Read more
A new RNAi treatment candidate for chronic hepatitis B (HBV) infection called ALN-HBV, has entered a Phase 1/2 clinical trial to evaluate its safety and efficacy in healthy volunteers and HBV ... Read more
The U.S. Food and Drug Administration (FDA) approved Epclusa for the treatment of patients with chronic hepatitis C virus (HCV) infection. Epclusa can be used as a monotherapy for patients without cirrhosis (late ... Read more
Enanta Pharmaceuticals has begun dosing chronic hepatitis C virus (HCV) patients with its investigational drug EDP-494 as part of a proof-of-concept study designed to demonstrate the medicine’s efficacy in a subset of patients with ... Read more
New interferon-free treatments for patients with hepatitis C were shown to decrease hypertension of the portal vein — which carries blood from the gut to the liver — decreasing the risk of ... Read more
A gene whose mutations cause a rare human genetic disease associated with defects in lipid storage may be involved in the assembly and release of the hepatitis C virus (HCV), according ... Read more